EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

Hirofumi Yoshino iD, Seiya Yokoyama, Motoki Tamai, Shunsuke Okamura, Sayaka Iizasa, Takashi Sakaguchi, Yoichi Osako, Satoru Inoguchi, Ryosuke Matsushita, Yasutoshi Yamada, Masayuki Nakagawa, Shuichi Tatarano und 2 weitere

FEBS Open Bio · 2023

DOI: 10.1002/2211-5463.13616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2023. Verfasst von Hirofumi Yoshino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine‐resistant and cisplatin‐resistant BCs do not exhibit cross‐resistance, and that these BCs exhibit different mRNA patterns, as revealed using RNA sequence analysis. To overcome drug resistance, we used the newly developed pan‐RAS inhibitor Compound 3144. Compound 3144 inhibited cell viability through suppression of RAS‐dependent signaling in gemcitabine‐ and cisplatin‐resistant BCs. RNA sequencing revealed that several genes and pathways, particularly those related to the cell cycle, were significantly downregulated in Compound 3144‐treated BCs. These findings provide insights into potential therapeutic strategies for treating BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsUrinary Bladder NeoplasmsHumansGemcitabineCisplatinDrug Resistance, NeoplasmDeoxycytidine

Stichwörter der Autor:innen

RASbladder cancercisplatin resistancegemcitabine resistancepan-RAS inhibitor

Substanzen

GemcitabineCisplatinAntineoplastic AgentsDeoxycytidine

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.
  • Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.

ORCID-Profile: Hirofumi Yoshino, Hideki Enokida

Förderung

  • Japan Society for the Promotion of Science
  • Takeda Science Foundation

Zitieren

APA

Yoshino, H., Yokoyama, S., Tamai, M., Okamura, S., Iizasa, S., Sakaguchi, T., Osako, Y., Inoguchi, S., Matsushita, R., Yamada, Y., Nakagawa, M., Tatarano, S., Tanimoto, A., & Enokida, H. (2023). Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13616

Vancouver

Yoshino H, Yokoyama S, Tamai M, Okamura S, Iizasa S, Sakaguchi T, et al. Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor. FEBS Open Bio. 2023. doi:10.1002/2211-5463.13616

BibTeX
@article{Yoshino2023,
  author = {Yoshino, Hirofumi and Yokoyama, Seiya and Tamai, Motoki and Okamura, Shunsuke and Iizasa, Sayaka and Sakaguchi, Takashi and Osako, Yoichi and Inoguchi, Satoru and Matsushita, Ryosuke and Yamada, Yasutoshi and Nakagawa, Masayuki and Tatarano, Shuichi and Tanimoto, Akihide and Enokida, Hideki},
  title = {Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor},
  journal = {FEBS Open Bio},
  year = {2023},
  doi = {10.1002/2211-5463.13616}
}
Kostenlos starten →